一项新研究发现,一个混合吸入器将儿童哮喘发作率削减45%,没有生长副作用。 A new study finds a combo inhaler cuts asthma attacks in kids by 45% with no growth side effects.

发表在"柳叶刀"杂志上的一项大型国际研究发现,与标准的沙布塔摩尔吸入剂相比,与布德森化物和福莫特醇联合吸入剂的使用在5至15岁儿童中可减少45%的喘发作,而增长,肺功能或喘控制方面没有显著差异. A large international study published in The Lancet found that a combination inhaler with budesonide and formoterol reduces asthma attacks in children aged 5 to 15 by 45% compared to the standard salbutamol inhaler, with no significant differences in growth, lung function, or asthma control. 援外社的研究涉及新西兰360名儿童,研究显示,攻击率从每名儿童每年0.41人降至0.23人,即每100名转班儿童每年受攻击人数减少18人。 The CARE study, involving 360 children in New Zealand, showed attack rates dropped from 0.41 to 0.23 per child per year, meaning 18 fewer attacks annually for every 100 children switched. 研究人员表示,成果支持更新全球儿童哮喘准则,使其符合成人标准,有可能改善数百万人的成果,缩小护理差距。 Researchers say the results support updating global asthma guidelines for children to match adult standards, potentially improving outcomes for millions and reducing care disparities. 尽管在大流行病期间进行了治疗,但现实世界的设计强化了研究结果,专家认为治疗是儿科哮喘护理的变革性进步。 Though conducted during the pandemic, the real-world design strengthens the findings, and experts call the treatment a transformative advance in pediatric asthma care.